|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2008
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
gptkb:B01AF01
|
|
gptkbp:bioavailability
|
80-100%
|
|
gptkbp:brand
|
gptkb:Xarelto
|
|
gptkbp:CASNumber
|
366789-02-8
|
|
gptkbp:contraindication
|
active pathological bleeding
severe hypersensitivity to rivaroxaban
|
|
gptkbp:drugClass
|
gptkb:anticoagulant
|
|
gptkbp:eliminatedIn
|
renal
biliary
|
|
gptkbp:eliminationHalfLife
|
5-9 hours (young), 11-13 hours (elderly)
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasBoxedWarning
|
spinal/epidural hematoma risk
increased risk of thrombotic events after premature discontinuation
|
|
gptkbp:hasInChIKey
|
MUNRUTXBAQUQKT-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
gptkb:C19H18ClN3O5S
|
|
gptkbp:hasSMILES
|
CC1=NN(C2=C1C=CC(=C2)Cl)C(=O)C3=CC=C(C=C3)S(=O)(=O)NC(=O)O
|
|
gptkbp:hasUNII
|
Y6O7T4G8P9
|
|
gptkbp:indication
|
prevention of venous thromboembolism after hip or knee replacement surgery
treatment of deep vein thrombosis
treatment of pulmonary embolism
prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
|
|
gptkbp:legalStatus
|
prescription only
patented
|
|
gptkbp:manufacturer
|
gptkb:Bayer
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
gptkb:direct_factor_Xa_inhibitor
|
|
gptkbp:metabolism
|
hepatic (CYP3A4, CYP2J2, CYP-independent mechanisms)
|
|
gptkbp:molecularWeight
|
435.88
|
|
gptkbp:name
|
gptkb:Rivaroxaban
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
92-95%
|
|
gptkbp:PubChem_CID
|
gptkb:DB06292
9875401
D08917
68547
8058577
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
bleeding
dyspepsia
|
|
gptkbp:synonym
|
gptkb:BAY_59-7939
|
|
gptkbp:target
|
coagulation factor Xa
|
|
gptkbp:bfsParent
|
gptkb:dapagliflozin
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB06292
|